187 related articles for article (PubMed ID: 36410817)
1. Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study.
Millgate E; Griffiths K; Egerton A; Kravariti E; Casetta C; Deakin B; Drake R; Howes OD; Kassoumeri L; Khan S; Lankshear S; Lees J; Lewis S; Mikulskaya E; Oloyede E; Owens R; Pollard R; Rich N; Smart S; Segev A; Verena Sendt K; MacCabe J;
BMJ Open; 2022 Nov; 12(11):e062570. PubMed ID: 36410817
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.
Millgate E; Kravariti E; Egerton A; Howes OD; Murray RM; Kassoumeri L; Donocik J; Lewis S; Drake R; Lawrie S; Murphy A; Collier T; Lees J; Stockton-Powdrell C; Walters J; Deakin B; MacCabe J
BMJ Open; 2021 Nov; 11(11):e054160. PubMed ID: 34824121
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
[TBL] [Abstract][Full Text] [Related]
5. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study.
Millgate E; Smart SE; Pardiñas AF; Kravariti E; Ajnakina O; Kępińska AP; Andreassen OA; Barnes TRE; Berardi D; Crespo-Facorro B; D'Andrea G; Demjaha A; Di Forti M; Doody GA; Kassoumeri L; Ferchiou A; Guidi L; Joyce EM; Lastrina O; Melle I; Pignon B; Richard JR; Simonsen C; Szöke A; Tarricone I; Tortelli A; Vázquez-Bourgon J; Murray RM; Walters JTR; MacCabe JH;
Schizophr Res; 2023 May; 255():173-181. PubMed ID: 37001392
[TBL] [Abstract][Full Text] [Related]
6. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study.
Levine SZ; Rabinowitz J; Case M; Ascher-Svanum H
J Clin Psychopharmacol; 2010 Aug; 30(4):446-9. PubMed ID: 20631562
[TBL] [Abstract][Full Text] [Related]
7. Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Tenjin T; Miyamoto S; Miyake N; Ogino S; Kitajima R; Ojima K; Arai J; Teramoto H; Tsukahara S; Ito Y; Tadokoro M; Anai K; Funamoto Y; Kaneda Y; Sumiyoshi T; Yamaguchi N
Hum Psychopharmacol; 2012 Jan; 27(1):90-100. PubMed ID: 22278973
[TBL] [Abstract][Full Text] [Related]
8. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
9. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
10. Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design.
Nasib LG; Sommer IE; Winter-van Rossum I; de Vries J; Gangadin SS; Oomen PP; Judge G; Blom RE; Luykx JJ; van Beveren NJM; Veen ND; Kroken RA; Johnsen EL
Trials; 2020 Jun; 21(1):492. PubMed ID: 32513294
[TBL] [Abstract][Full Text] [Related]
11. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
12. Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment.
Duan L; Tian C; Fu C; He J; Dai J; Shao X; Zhu G
J Psychiatr Res; 2022 Aug; 152():278-288. PubMed ID: 35759980
[TBL] [Abstract][Full Text] [Related]
13. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
[TBL] [Abstract][Full Text] [Related]
14. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. [An effect of antipsychotic and anticholinergic treatment on cognitive function in patients with schizophrenia].
Tumova MA; Stepanova AA; Zazulina YS; Guseinova ZT; Zaitseva MM; Dyment IV; Kotsyubinsky AP; Ivanov MV
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):80-85. PubMed ID: 37490669
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
19. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.
Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe S; French P; Hutton P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TR; Davies L; Shields G; Buck D; Tully S; Kingdon D
Health Technol Assess; 2019 Feb; 23(7):1-144. PubMed ID: 30806619
[TBL] [Abstract][Full Text] [Related]
20. Relationship between changes in metabolic syndrome constituent components over 12 months of treatment and cognitive performance in first-episode schizophrenia.
Luckhoff HK; Kilian S; Olivier MR; Phahladira L; Scheffler F; du Plessis S; Chiliza B; Asmal L; Emsley R
Metab Brain Dis; 2019 Apr; 34(2):469-476. PubMed ID: 30604027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
